Iovance (IOVA) raised 2026 revenue guidance 15% to $410-420M driven by strong Q2 results (+66% YoY) and increasing patient demand, with key catalysts approaching for first-line melanoma and NSCLC expansion that could significantly expand addressable market. Key risks include clinical trial failures for pipeline expansion, competitive threats, and execution risk in manufacturing scale-up.

IOVA has 21% short interest despite FDA approval, presenting a potential short squeeze opportunity with upcoming catalysts. The post suggests bullish sentiment due to the disconnect between approval status and short positioning, though execution risk remains on catalyst delivery.

Post appears to be incomplete or unclear, containing only the ticker symbol IOVA with question marks and no substantive analysis or thesis presented. Cannot determine investment rationale or risks from the limited content.

The investor has made a large $900k position in IOVA at $4.00 per share, indicating bullish conviction in the stock. The key risks would include potential clinical trial failures, regulatory setbacks, competitive pressures in the biotech sector, and the inherent volatility and capital requirements of small-cap pharmaceutical companies.